Portfolio company
Epics Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology company develops small-molecule RNA epigenetic modulators to treat patients with solid tumours and autoimmune diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Epitome Therapeutics
This biotechnology firm develops an epigenome editing platform for programmable gene expression to treat patients with rare genetic and metabolic disorders.
Epana Bio
This company develops precision T-cell engagers and biologics using artificial intelligence and genomics to treat patients with autoimmune diseases.
Epicrispr
This company develops epigenomic therapies to control gene expression in patients with complex diseases.
Typewriter Therapeutics
The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.
EpiBiologics
This company develops bispecific antibodies to degrade extracellular proteins for patients with cancer and autoimmune disorders.
Egle Therapeutics
This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.
Epana
The company develops precision immune cell therapies and diagnostic atlases using genomics and artificial intelligence for patients with autoimmune diseases.
Regcell
This biotechnology company develops regulatory T-cell therapies using an epigenetic reprogramming platform to treat patients with autoimmune diseases and inflammatory conditions.